Rodin Therapeutics
25 First Street #303
Cambridge
Massachusetts
United States
Website: http://rodintherapeutics.com/
Email: ankit@atlasventure.com
20 articles about Rodin Therapeutics
-
While the conditions surrounding the City by the Bay are in a negative light, there is still a significant amount of positive news coming out of the conference.
-
Top Biopharma M&As in 2019
1/10/2020
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019. -
Alkermes to Acquire Rodin Therapeutics
11/18/2019
Acquisition to Expand Alkermes' Presence in CNS to a Wide Range of Neurodegenerative Diseases Through Epigenetic Control of Synaptogenesis
-
Under the terms of the deal, Alkermes is paying $100 million in cash upfront. Rodin will be eligible for future payments of up to $850 million based on clinical and regulatory milestones and sales thresholds.
-
Rodin Therapeutics Appoints Experienced Biotechnology Investor Ajim Tamboli as Chief Financial Officer
8/6/2019
Rodin Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for synaptopathies, announced the appointment of veteran investment professional Ajim Tamboli as chief financial officer.
-
Rodin Therapeutics Announces Positive Phase 1 Results Supporting Continued Development of RDN-929 for Treatment of Neurologic Diseases
6/25/2019
Compound Designed to Enhance Synaptic Integrity and Improve Learning, Memory and Function
-
Rodin Therapeutics Announces Initiation of Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases
12/12/2018
Rodin Therapeutics today announced the initiation of a Phase 1 clinical trial of the company’s lead candidate, RDN-929, a potent and selective HDAC-CoREST inhibitor.
-
Rodin Therapeutics Announces Publication of Paper Demonstrating Pro-Synaptic Effects of CoREST-Selective Inhibitors
12/5/2018
Rodin Therapeutics today announced the publication of a scientific paper demonstrating the efficacy of novel compounds which selectively inhibit the HDAC-CoREST complex.
-
Rodin Therapeutics Launches Clinical Trial of Neuroimaging Tool for Measurement of Synaptic Density
10/18/2018
Rodin Therapeutics today announced the launch of a clinical trial to assess the performance of a new PET ligand that can measure synaptic density in the living brain.
-
Rodin Therapeutics Announces Award of Grant Support From The Michael J. Fox Foundation to Advance Novel Treatment Strategy for Parkinson’s Disease
11/13/2017
MJFF is supporting Rodin’s work through two rounds of grant funding, totaling approximately $600,000.
-
Rodin Nabs $27 Million to Carry HDAC Complex Compound into the Clinic
9/21/2017
-
Sans Biogen's $485 Million Buyout Option, Rodin Nabs $27 Million For Alzheimer's
9/18/2017
-
Rodin Advances Synaptic Resilience Strategy With $27 Million In Financing And Expands Board Of Directors
9/18/2017
-
Rodin Expands Leadership Team And Advisory Boards To Advance Novel, Selective HDAC Inhibitors Towards The Clinic
9/22/2016
-
Rodin and Biogen Ink Possible Acquisition Deal for up to $485 Million
1/6/2016
-
Rodin Therapeutics Appoints Samantha Singer To Board Of Directors
12/21/2015
-
Rodin Therapeutics Appoints Adam J. Rosenberg As Chief Executive Officer
10/6/2015
-
Johnson & Johnson Shows Off Deals With Six Boston Biotech Firms— Padlock Therapeutics, Energesis Pharmaceuticals, Navitor Pharmaceuticals, Ascelegen Therapeutics, Minerva Neurosciences, Inc., And Rodin Therapeutics
6/20/2014
-
Cambridge-Based Biotech Rodin Therapeutics Snags $12.9 Million Series A Financing
5/30/2014
-
Atlas Startup, Rodin Therapeutics, Hopes to Rewire Neurons to Improve Memory
8/14/2013